Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda Pharmaceutical Company Limited: Takeda Announces ...

Takeda Pharmaceutical Company Limited / JP3463000004

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab a Potential Best-in-Class Anti-CD38 Monoclonal Antibody for Primary Immune Thrombocytopenia ...

Hape Kerkeling macht sich am Tag der Seltenen Erkrankungen ...

Hape Kerkeling macht sich am Tag der Seltenen Erkrankungen stark für die Waisen der Medizin / Spezialfolge des Podcasts Unglaublich krank

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

GNW-Adhoc: Accumulus Synergy startet mit Spannung erwartete ...

BURLINGAME, Kalifornien, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc.

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

EQS-News: Der Future of Health Grant gewinnt mit Unisanté ...

Der Future of Health Grant gewinnt mit Unisanté einen zehnten starken Partner CSS Kranken-Versicherung AG / Schlagwort(e): Sonstiges Der Future of Health Grant gewinnt mit ...

Avec l arrivée d Unisanté le Future of Health Grant s ...

CSS Kranken-Versicherung AG

Con l'arrivo di Unisanté il Future of Health Grant si arricchisce ...

CSS Kranken-Versicherung AG

Der Future of Health Grant gewinnt mit Unisanté einen zehnten ...

CSS Kranken-Versicherung AG

The world’s 30 Best Places to Work for 2023 revealed

Best Places to Work

Takeda Receives Positive CHMP Opinion for HYQVIA? as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP28

Takeda?s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura ...

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279 an Investigational Oral Once-Daily TYK2 Inhibitor in Patients with Active Psoriatic Arthritis at American ...

NurExone Biologic: Hoffnung für Millionen bei Rückenmarksverletzungen ...

Dr. Reuter Investor Relations / DE0000000014

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda berichtet Verkauf seiner Atemwegstherapeutika-Sparte ...

Takeda Pharmaceutical Company Limited (TOKYO:4502) hat heute den Abschluss des Vertrags zum Verkauf seiner Atemwegstherapeutika-Sparte an AstraZeneca berichtet.

Takeda Pharmaceutical Company Limited (TOKYO:4502) hat heute den ...

Takeda berichtet Verkauf seiner Atemwegstherapeutika-Sparte an AstraZeneca.

Takeda. ISIN: JP3463000004 WKN: 853849

Takeda

Takeda. ISIN: JP3463000004 WKN: 853849

Takeda

Takeda. ISIN: JP3463000004 WKN: 853849

Takeda

Das große EMFIS Marktupdate (EM Stock Picker No. 20)

Tokio: Takeda rutscht ab. Spekulation um Jahresüberschuß ...

Tokio: Takeda rutscht ab

EMFIS EM Stocks Review: Asien. Korea und Taiwan im Plus ...

EMFIS EM Stocks Review: Asien